Clinical Trials

246 enrolled

Multiple Myeloma

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05434689 2026-04-15

COMMANDER

80 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07463807 2026-04-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

162 enrolled

Multiple Myeloma

NCT01297764 2026-03-23

QUAD

17 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07479979 2026-03-23

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

66 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT02937571 2025-11-20

High Dose Carfilzomib for Newly Diagnosed Myeloma

29 enrolled 10 charts

Multiple Myeloma

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

19 enrolled

Multiple Myeloma, Recurrence

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT01857115 2024-11-13

wCCyd

63 enrolled

Disease, Multiple Myeloma

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02073097 2024-05-29

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

48 enrolled 18 charts

Lymphoma, Large B-Cell, Diffuse

NCT01941316 2024-05-09

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

GastrointestinalGynecologicThoracic

78 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

27 enrolled 13 charts

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT02056756 2024-02-20

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

63 enrolled

Multiple Myeloma

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

11 enrolled 11 charts

Multiple Myeloma

NCT02185820 2023-07-03

CPD

57 enrolled

Multiple Myeloma

NCT02204241 2023-07-03

CCD

36 enrolled

Disease, Multiple Myeloma

NCT01677858 2022-09-23

CHAMPION 1

116 enrolled 28 charts

Multiple Myeloma

NCT05060627 2022-09-08

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

60 enrolled

Multiple Myeloma

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

136 enrolled

Multiple Myeloma

NCT03141203 2022-05-18

RomiCar

50 enrolled

Lymphoma, T-Cell, Peripheral

NCT01496118 2022-02-02

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

80 enrolled 20 charts

Multiple Myeloma

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

LymphoidOther hematologic neoplasmPlasma cell

53 enrolled 17 charts

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT01962792 2021-12-21

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

84 enrolled 14 charts

Multiple Myeloma

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

14 enrolled 9 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03795597 2021-04-26

BuMelCarAuto

Phase 1/2 Unknown

36 enrolled

Multiple Myeloma

NCT02545907 2021-04-15

CATALYST

10 enrolled 14 charts

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01842308 2020-09-01

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

50 enrolled 14 charts

Multiple Myeloma

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

83 enrolled 31 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT01246063 2019-04-08

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

40 enrolled 20 charts

Multiple Myeloma

NCT01690143 2018-08-07

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

45 enrolled 10 charts

Multiple Myeloma

NCT01792102 2018-03-05

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

Phase 1/2 Unknown

38 enrolled

Multiple Myeloma

NCT01057225 2017-12-12

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

64 enrolled 13 charts

Multiple Myeloma

NCT01987232 2017-08-28

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

32 enrolled 18 charts

Thoracic

Small Cell Lung Carcinoma

NCT00531284 2017-08-15

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

GenitourinaryGynecologicLymphoidPlasma cellThoracic

184 enrolled 36 charts

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Lymphoma, Multiple Myeloma, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02802163 2017-04-25

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Phase 1/2 Withdrawn

Multiple Myeloma

NCT01029054 2017-01-30

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

53 enrolled 7 charts

Multiple Myeloma

NCT01658904 2016-06-01

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Other hematologic neoplasmPlasma cell

3 enrolled 6 charts

Leukemia, Plasma Cell, Multiple Myeloma

NCT01279694 2016-04-13

CARMYSAP

72 enrolled